Beth Silverstein
Carl Osborne

DOI:https://doi.org/10.5912/jcb448


Abstract:

Scientists or entrepreneurs in the area of biotechnology seeking to convert their discoveries into commercially viable products can find the effort daunting given that it combines the well-recognised challenges inherent in any start-up company, the complex and changing regulatory requirements for marketing approval, and the uncertainty of biology. Significant capital is required at each step from discovery to manufacture to preclinical and clinical testing, and venture capital investors are an important source of this funding. This paper provides some basic guidance to early stage companies on how to attract venture capital funding.

Keywords:venture capital ,drug development ,business plan ,en ,